XIENCE™ Family of Drug-Eluting Stents

The World's Leading Drug-Eluting Stents (DES), with Unparalleled Clinical Outcomes¹

XIENCE™ Stent Evidence

XIENCE™ Stent is the DES that delivers consistently outstanding short- and long-term patient outcomes.2

In fact, XIENCE™ Stent consistently has the lowest rate of late and very late stent thrombosis (ST)—not only a year but a decade after the intervention—providing evidence that the XIENCE™ Stent's unparalleled patient outcomes last far beyond the intervention.1
 

Exceptional Long-Term Patient Data

XIENCE™ Stent’s Consistently Low Rates of Late and Very Late Stent Thrombosis1

XIENCE Stent showed consistently low stent thrombosis rates of 0% at 1-5 years, and in many patients types, including complex patients

7-Year TLR Data

Long-term restenosis rates are also low, as shown by freedom from clinically driven target lesion revascularization (CD-TLR) at 7 years.9

93% of patients were free from target lesion revascularization 7 years after the XIENCE Stent implant

Optimal Device Success

XIENCE™ Stent data shows consistent device success—and in all types of patients and lesions.

XIENCE Stent data reveal a 99% acute success rate, showing optimal device success

Improved Quality of Life with XIENCE™ Stent11

XIENCE™ Stent has been shown to improve the quality of life of left main patients out to 3 years with 81% of patients reporting that they were angina free.

See the long-term results in complex patients treated with XIENCE™ Stent.

Improved QOL at 3 Years11

81% of patients had no angina symptoms 3 years after XIENCE Stent implant
Manuals & Technical Resources

Manuals & Technical Resources

Order Cardiovascular Products

Cardiovascular Products

Customer Service

Customer Service

References

  1. Zanchin C, et al. JACC Cardiovasc Interv. 2019;12(17):1665-1675. Serruys P, et al. N Engl J Med. 2010;363:136-146. Shiomi H, et al. JACC Cardiovasc Interv. 2019;12:637-647. Kufner S, et al. Circulation. 2019:139(3):325-333. Palmerini T, et al. Lancet. 2013;379:1393-1402. Bangalore S, et al. Circulation. 2012;125:2873-2891. Bangalore S, et al. Circ Cardiovasc Interv. 2013;6(6):378-390. Pilgrim T, et al. Lancet. 2014;384:2111-2122. Pilgrim T, et al. Lancet. 2018;392:737-746. Data on file at Abbott.
  2. Zanchin C. et al. JACC Cardiovasc Interv. 2019;12(17):1665-1675. Serruys P, et al. N Engl J Med. 2010;363:136-146. Shiomi H, et al. JACC Cardiovasc Interv. 2019;12:637-647. Kufner S, et al. Circulation. 2019:139(3):325-333.
  3. Mehran R, et al. TCT Connect - XIENCE 28/90.
  4. Von Birgele C, et al. J Am Coll Cardiol. 2012;59(15):1350-1361.
  5. Van Geuns RJ, et al. TCT 2019, IDEAL-LM.
  6. Chevalier B, et al. EuroIntervention. 2018;13(13):1561-1564.
  7. Gao R, et al. TCT 2019, ABSORB China.
  8. Kufner S, et al. Circulation. 2019:139(3):325-333.
  9. Shiomi H, et al. JACC Cardiovasc Interv. 2019;12(7):637-647.
  10. Saito S, et al. Eur Heart J. 2014;35:2021-2031. Saito S, et al. EuroIntervention. 2019;15(11):e1006-e1013. Natsuaki M, et al. J Am Coll Cardiol. 2013;62(3):181-190. Stone G, et al. Lancet. 2018:392:1530-40.
    Note: 99% was the lowest device success rate.
  11. Baron SJ, et al. J Am Coll Cardiol. 2017;70(25):3113-3122.

MAT-2101782 v2.0